GGrantIndex
← Search

DNA Analysis Facility

$2,882P30FY2012CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications, trials & patents

Trial NCT07407920Trial NCT07349641Trial NCT06651580Trial NCT05681026Trial NCT05223036Trial NCT05078866Trial NCT05057312Trial NCT05054296Trial NCT05044546Trial NCT05023967Trial NCT05011045Trial NCT04875728Trial NCT04870645Trial NCT04810091Trial NCT04751422Trial NCT04740164Trial NCT04668300Trial NCT04615013Trial NCT04505267Trial NCT04484909Trial NCT04483349Trial NCT04481204Trial NCT04474301Trial NCT04458610Trial NCT04447222Trial NCT04435691Trial NCT04430725Trial NCT04407247Trial NCT04373720Trial NCT04317781Trial NCT04311723Trial NCT04310826Trial NCT04310397Trial NCT04265430Trial NCT04257045Trial NCT04256941Trial NCT04239989Trial NCT04239976Trial NCT04239157Trial NCT04236882Trial NCT04228042Trial NCT04220827Trial NCT04220775Trial NCT04220008Trial NCT04219969Trial NCT04219904Trial NCT04216732Trial NCT04216563Trial NCT04216524Trial NCT04216472Trial NCT04215029Trial NCT04200534Trial NCT04199026Trial NCT04196972Trial NCT04189783Trial NCT04189770Trial NCT04189757Trial NCT04188418Trial NCT04188405Trial NCT04186884Trial NCT04186832Trial NCT04185337Trial NCT04181463Trial NCT04171622Trial NCT04171219Trial NCT04171037Trial NCT04169763Trial NCT04169737Trial NCT04169542Trial NCT04160052Trial NCT04151082Trial NCT04150939Trial NCT04140487Trial NCT04135326Trial NCT04134208Trial NCT04132843Trial NCT04132505Trial NCT04132440Trial NCT04129138Trial NCT04128748Trial NCT04128501Trial NCT04127721Trial NCT04125914Trial NCT04119037Trial NCT04106843Trial NCT04106245Trial NCT04090619Trial NCT04090567Trial NCT04087057Trial NCT04083378Trial NCT04082572Trial NCT04074746Trial NCT04066894Trial NCT04062305Trial NCT04062266Trial NCT04058964Trial NCT04054245Trial NCT04054167Trial NCT04054154Trial NCT04053517

Abstract

Since its inception in 1991, the goal of the DNA Analysis Facility (DAF) has been to provide MDACC investigators with reliable nucleic acid analysis using state-of-the-art technology to provide a high level of technical expertise in a centralized facility. Today, 7 highly-skilled technical staff operate 3 robotic workstations: a QiagenSOOO Biorobot, a Qiagen 8000 Biorobot, and a Beckman Biomek 2000. The staff also operate a Transgenomic WAVE mutation detection system, an Applied Biosystems 3730 XL genetic analyzer, an Applied Biosystems 3130 genetic analyzer, an Applied Biosystems 3100 genetic analyzer and 4 Applied Biosystems real-time PCR instruments; the 7000, 7300, 7500 and 7900 with low density array. The DAF performs automated DNA sequencing, gene resequencing, fluorescent fragment analysis, highthroughput SNP analysis, murine DNA extraction and genotyping by real-time PCR, quantitative gene expression analysis and real-time PCR assay design. Provision of these essential services has freed investigators to focus their efforts on characterizing the molecular and biological functions of their target genes. A shared resource director, co-director, and a 5-member oversight committee direct the development of the DAF. This committee meets annually to evaluate the scientific and financial performance of the facility. The co-director manages the daily activities of the DAF. In the current grant period, the institution invested $569,500 in the DAF for the purchase of new equipment, in addition to providing a new 1,600 sq ft lab at a cost of $876,000. Funding for the DAF is provided by the CCSG (38%) and user fees (62%). The DAF successfully processed 560,413 samples in the last 5 years, representing 280 investigators from 20 programs. The total number of samples processed increased 198% compared to the previous grant period. All services had more than 75% use by peer-reviewed investigators, with more than 90% of samples processed for peer-reviewed investigators. Output in DNA sequencing during the present grant period compared to the last showed an increase of 130%, while Fragment analysis increased 158%. Newer services have also shown significant growth. Murine genotyping increased 103%, gene resequencing increased 718% (2 years) and 14,600 SNPs were determined using the SNPlex service. The DAF recently introduced a quantitative gene expression analysis service. This service includes RNA quantification, RNA QC, reverse transcription and assay set-up. The facility plans to expand this service to include microRNA assays.

View original record on NIH RePORTER →